Lauren Elizabeth Hamlett, PA
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Lauren Elizabeth Hamlett’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G58248 · Cancelled
Licence status: Cancelled · since 1986 · University of Michigan Medical School.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$60,289
Medicare paid this office $60,289 for 431 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 110 | $14,256 | $104 |
| Return visit (30+ min) | 110 | $9,951 | $69 |
| Long return visit (40+ min) | 52 | $8,168 | $136 |
| Return visit (30+ min) | 70 | $7,894 | $97 |
| Short return visit (20+ min) | 74 | $4,142 | $46 |
See all 12 services
| Long return visit (40+ min) | 110 | $14,256 | $104 |
| Return visit (30+ min) | 110 | $9,951 | $69 |
| Long return visit (40+ min) | 52 | $8,168 | $136 |
| Return visit (30+ min) | 70 | $7,894 | $97 |
| Short return visit (20+ min) | 74 | $4,142 | $46 |
| Insertion of lower leg neurostimulator electrode | 27 | $4,125 | $22 |
| Short return visit (20+ min) | 48 | $3,304 | $66 |
| New patient visit (45+ min) | 19 | $1,755 | $92 |
| New patient visit (60+ min) | 12 | $1,560 | $130 |
| Short return visit | 11 | $477 | $43 |
| Short return visit | 17 | $402 | $22 |
| Electronic assessment of bladder emptying | 17 | $109 | $6 |
Who their Medicare patients are
431 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 16% · Women 27% · Also on Medicaid 24% · Health risk score 1.56. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 68% · Diabetes 29% · Coronary heart disease 29% · Chronic kidney disease 28% · Cancer 24% · Atrial fibrillation 19% · Depression 19% · Heart failure 16% · COPD 14% · Dementia 9% · Stroke 8%.
The office billed $347,136, Medicare allowed $80,794 and paid $60,289; for 916 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 431 | 916 | 75 | 1.56 | $347,136 | $60,289 |
| 2023 | 458 | 1,039 | 74 | 1.64 | $278,921 | $59,803 |
| 2022 | 420 | 1,043 | 75 | 1.73 | $230,808 | $58,494 |
| 2021 | 433 | 1,079 | 73 | 1.62 | $214,756 | $56,371 |
| 2020 | 358 | 1,044 | 72 | 2.15 | $260,270 | $46,866 |
| 2019 | 207 | 691 | 72 | 1.93 | $419,880 | $33,009 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Long return visit (40+ min) | 151 | $19,975 | $105 |
| Return visit (30+ min) | 179 | $16,751 | $71 |
| Short return visit (20+ min) | 102 | $6,996 | $49 |
| Insertion of lower leg neurostimulator electrode | 32 | $5,010 | $21 |
| New patient visit (45+ min) | 40 | $3,860 | $97 |
| New patient visit (60+ min) | 20 | $2,839 | $142 |
| Short return visit | 38 | $1,123 | $23 |
| Insertion of temporary bladder tube | 13 | $1,092 | $19 |
| New patient visit (30+ min) | 15 | $837 | $56 |
| Electronic assessment of bladder emptying | 17 | $100 | $6 |
2022: 12 services
| Long return visit (40+ min) | 146 | $19,062 | $106 |
| Return visit (30+ min) | 176 | $17,015 | $69 |
| Short return visit (20+ min) | 76 | $4,784 | $45 |
| New patient visit (60+ min) | 35 | $4,747 | $136 |
| Insertion of lower leg neurostimulator electrode | 33 | $4,609 | $21 |
| New patient visit (45+ min) | 43 | $3,951 | $92 |
| Insertion of temporary bladder tube | 22 | $1,101 | $17 |
| Short return visit | 17 | $743 | $23 |
| New patient visit (30+ min) | 11 | $581 | $53 |
| Simple insertion of temporary bladder tube | 13 | $460 | $18 |
| Simple bladder irrigation and/or instillation | 21 | $458 | $22 |
| Electronic assessment of bladder emptying | 50 | $309 | $6 |
2021: 11 services
| Return visit (30+ min) | 191 | $16,606 | $71 |
| Short return visit (20+ min) | 147 | $10,418 | $51 |
| Long return visit (40+ min) | 70 | $8,366 | $109 |
| New patient visit (45+ min) | 83 | $8,171 | $98 |
| Insertion of lower leg neurostimulator electrode | 25 | $4,137 | $22 |
| New patient visit (60+ min) | 22 | $3,038 | $138 |
| Short return visit | 30 | $1,402 | $27 |
| Simple bladder irrigation and/or instillation | 43 | $1,192 | $22 |
| Insertion of temporary bladder tube | 20 | $819 | $18 |
| Simple insertion of temporary bladder tube | 23 | $617 | $17 |
| Electronic assessment of bladder emptying | 52 | $392 | $6 |
2020: 19 services
| Return visit (30+ min) | 95 | $7,431 | $61 |
| Return visit (30+ min) | 86 | $5,961 | $61 |
| Diagnostic exam of bladder and urethra using an endoscope | 32 | $4,906 | $144 |
| New patient visit (45+ min) | 34 | $3,416 | $100 |
| New patient visit (45+ min) | 30 | $2,466 | $82 |
| Short return visit (20+ min) | 50 | $2,459 | $40 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 12 | $2,425 | $202 |
| Insertion of lower leg neurostimulator electrode | 16 | $1,942 | $24 |
| New patient visit (60+ min) | 15 | $1,883 | $126 |
| Short return visit (20+ min) | 33 | $1,644 | $48 |
| Long return visit (40+ min) | 16 | $1,492 | $88 |
| Long return visit (40+ min) | 13 | $1,144 | $88 |
| Ultrasound measurement of bladder capacity after voiding | 94 | $934 | $7 |
| Simple bladder irrigation and/or instillation | 23 | $695 | $24 |
| Urinalysis, manual test | 73 | $336 | $3 |
| Electronic assessment of bladder emptying | 36 | $301 | $7 |
| Insertion of temporary bladder tube | 11 | $242 | $20 |
| Electronic assessment of bladder emptying | 17 | $122 | $6 |
| Manual urinalysis test with examination using microscope, non-automated | 13 | $53 | $4 |
2019: 10 services
| New patient visit (45+ min) | 50 | $5,347 | $107 |
| Short return visit (20+ min) | 74 | $4,207 | $49 |
| Return visit (30+ min) | 46 | $4,175 | $72 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $3,419 | $127 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 16 | $2,397 | $150 |
| Ultrasound measurement of bladder capacity after voiding | 107 | $1,564 | $10 |
| New patient visit (30+ min) | 20 | $1,467 | $73 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 14 | $501 | $36 |
| Electronic assessment of bladder emptying | 43 | $454 | $8 |
| Urinalysis, manual test | 88 | $385 | $3 |
Medicaid work
$101 in 2024
Medicaid paid $101 for 17 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 17 | $101 |
| 2024 | 17 | 1 | 17 | $101 |
| 2023 | 359 | 6 | 28 | $4,769 |
| 2022 | 225 | 3 | 24 | $4,091 |
| 2021 | 351 | 5 | 25 | $5,030 |
| 2020 | 213 | 3 | 26 | $3,221 |
See the largest Medicaid services in earlier years
2023
| Service | 90 | $2,683 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 138 | $977 |
| Hospital outpatient clinic visit for assessment and management of a patient | 27 | $778 |
| Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming | 19 | $149 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 72 | $137 |
| Return visit (30+ min) | 13 | $45 |
2022
| Service | 85 | $3,075 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 110 | $926 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 30 | $91 |
2021
| Service | 67 | $2,703 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 169 | $1,322 |
| Hospital outpatient clinic visit for assessment and management of a patient | 39 | $628 |
| Return visit (30+ min) | 12 | $230 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 64 | $147 |
2020
| Service | 61 | $2,241 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 85 | $826 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 67 | $155 |
Drugs they prescribed that Part D paid
$527,530
Pharmacies billed $527,530 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,795) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
1,172 generic and fewer than 11 brand-name prescriptions · $527,530 in drug cost · 205 antibiotic prescriptions to 95 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 367 | $296,501 | $808 |
| Myrbetriq | 186 | $162,021 | $871 |
| Tamsulosin | 402 | $8,671 | $22 |
| Premarin | 16 | $6,896 | $431 |
| Methenamine Hippurate | 62 | $6,482 | $105 |
See all 26 drugs
| Gemtesa | 367 | $296,501 | $808 |
| Myrbetriq | 186 | $162,021 | $871 |
| Tamsulosin | 402 | $8,671 | $22 |
| Premarin | 16 | $6,896 | $431 |
| Methenamine Hippurate | 62 | $6,482 | $105 |
| Renacidin | 14 | $5,080 | $363 |
| Trospium Chloride Er | 18 | $3,808 | $212 |
| Estradiol | 61 | $3,684 | $60 |
| Tadalafil | 12 | $2,768 | $231 |
| Finasteride | 151 | $2,750 | $18 |
| Dutasteride | 34 | $2,617 | $77 |
| Fesoterodine Fumarate Er | 12 | $2,080 | $173 |
| Tolterodine Tartrate Er | 14 | $1,427 | $102 |
| Nitrofurantoin | 13 | $1,308 | $101 |
| Alfuzosin Hcl Er | 70 | $966 | $14 |
| Desmopressin Acetate | 11 | $859 | $78 |
| Trospium Chloride | 15 | $811 | $54 |
| Cephalexin | 55 | $610 | $11 |
| Nitrofurantoin Mono-Macro | 50 | $542 | $11 |
| Solifenacin | 13 | $432 | $33 |
| Pentoxifylline | 11 | $421 | $38 |
| Sulfamethoxazole-Trimethoprim | 27 | $281 | $10 |
| Sildenafil Citrate | 12 | $119 | $10 |
| Amoxicillin-Clavulanate Potass | 12 | $111 | $9 |
| Ciprofloxacin | 13 | $75 | $6 |
| Levofloxacin | 11 | $70 | $6 |
Year by year
| 2024 | 1,795 | 451 | 0% (0) | None | $527,530 |
| 2023 | 1,874 | 444 | 0% (0) | 30% | $474,676 |
| 2022 | 1,358 | 353 | 0% (0) | None | $261,528 |
| 2021 | 815 | 281 | None | 25% | $146,443 |
| 2020 | 459 | 177 | None | 19% | $52,214 |
| 2019 | 116 | 68 | None | 11% | $6,006 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Gemtesa | 284 | $202,017 | $711 |
| Myrbetriq | 215 | $182,492 | $849 |
| Tamsulosin | 429 | $13,461 | $31 |
| Methenamine Hippurate | 71 | $10,057 | $142 |
| Estradiol | 59 | $5,877 | $100 |
| Trospium Chloride Er | 16 | $4,691 | $293 |
| Finasteride | 191 | $4,601 | $24 |
| Trospium Chloride | 40 | $2,523 | $63 |
| Tadalafil | 14 | $2,520 | $180 |
| Alfuzosin Hcl Er | 78 | $1,688 | $22 |
| Testosterone | 21 | $1,332 | $63 |
| Nitrofurantoin Mono-Macro | 52 | $1,226 | $24 |
| Cephalexin | 57 | $865 | $15 |
| Pentoxifylline | 19 | $681 | $36 |
| Solifenacin | 19 | $391 | $21 |
| Phenazopyridine | 11 | $344 | $31 |
| Amoxicillin-Clavulanate Potass | 22 | $333 | $15 |
| Sulfamethoxazole-Trimethoprim | 23 | $228 | $10 |
| Levofloxacin | 14 | $192 | $14 |
| Ciprofloxacin | 25 | $145 | $6 |
| Terazosin | 11 | $145 | $13 |
| Amitriptyline | 14 | $128 | $9 |
| Sildenafil Citrate | 15 | $78 | $5 |
2022: 18 drugs
| Myrbetriq | 252 | $171,082 | $679 |
| Gemtesa | 56 | $30,174 | $539 |
| Tamsulosin | 340 | $7,016 | $21 |
| Estradiol | 54 | $5,972 | $111 |
| Methenamine Hippurate | 39 | $4,342 | $111 |
| Trospium Chloride | 42 | $3,148 | $75 |
| Finasteride | 159 | $3,006 | $19 |
| Testosterone | 14 | $1,830 | $131 |
| Oxybutynin Chloride Er | 22 | $1,308 | $59 |
| Alfuzosin Hcl Er | 39 | $947 | $24 |
| Nitrofurantoin Mono-Macro | 27 | $698 | $26 |
| Pentoxifylline | 25 | $606 | $24 |
| Solifenacin | 14 | $434 | $31 |
| Cephalexin | 50 | $368 | $7 |
| Amoxicillin-Clavulanate Potass | 20 | $306 | $15 |
| Amitriptyline | 14 | $246 | $18 |
| Ciprofloxacin | 21 | $114 | $5 |
| Sulfamethoxazole-Trimethoprim | 16 | $86 | $5 |
2021: 14 drugs
| Myrbetriq | 173 | $107,702 | $623 |
| Premarin | 12 | $4,890 | $408 |
| Tamsulosin | 193 | $4,118 | $21 |
| Estradiol | 28 | $3,520 | $126 |
| Finasteride | 98 | $1,952 | $20 |
| Trospium Chloride | 39 | $1,756 | $45 |
| Oxybutynin Chloride Er | 24 | $816 | $34 |
| Nitrofurantoin Mono-Macro | 19 | $411 | $22 |
| Alfuzosin Hcl Er | 12 | $366 | $30 |
| Cephalexin | 39 | $243 | $6 |
| Amoxicillin-Clavulanate Potass | 19 | $219 | $12 |
| Fluconazole | 11 | $130 | $12 |
| Ciprofloxacin | 28 | $118 | $4 |
| Sulfamethoxazole-Trimethoprim | 13 | $64 | $5 |
2020: 12 drugs
| Myrbetriq | 61 | $35,790 | $587 |
| Estradiol | 40 | $6,212 | $155 |
| Oxybutynin Chloride Er | 25 | $1,191 | $48 |
| Tamsulosin | 80 | $1,083 | $14 |
| Finasteride | 45 | $608 | $14 |
| Nitrofurantoin Mono-Macro | 31 | $464 | $15 |
| Alfuzosin Hcl Er | 18 | $274 | $15 |
| Ciprofloxacin | 19 | $143 | $8 |
| Amoxicillin-Clavulanate Potass | 13 | $100 | $8 |
| Sulfamethoxazole-Trimethoprim | 19 | $98 | $5 |
| Fluconazole | 11 | $83 | $8 |
| Cephalexin | 12 | $66 | $6 |
2019: 3 drugs
| Oxybutynin Chloride Er | 13 | $503 | $39 |
| Nitrofurantoin Mono-Macro | 11 | $312 | $28 |
| Tamsulosin | 26 | $286 | $11 |
Money from drug and device companies
$21 in 2024
| 2024 | 1 | 1 | None | $21 |
| 2022 | 1 | 6 | None | $246 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Ams 700 | $21 | 1 payment
|
See the published payment
| Boston Scientific | Meals · 2024-07-22 | Ams 700 | $21 |
See earlier years (2022)
2022: $246
| Axonics | Axonics | $246 | 6 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1861989873
- Licence
- CA 58248, TX PA11775California G58248: Cancelled
- Trained
- University of Texas Southwestern Medical School at Dallas, 2017
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, surgical (363AS0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2018-04-16
- NPI last updated
- 2025-12-18
- NPI record certified
- 2025-12-18
This is when the NPI record was last certified, not a medical board exam.